Safety, Tolerance, and Pharmacokinetics of BILN 2061 ZW in Healthy Male Subjects, Combined With Preliminary Evaluation of Food Effect

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: BILN 2061 ZW single rising doses; Drug: BILN 2061 ZW fixed dose; Drug: Placebo; Other: Standardized breakfast

• Registration Number: NCT02268760
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

To assess the safety, tolerance and pharmacokinetics of 5 mg to 2400 mg BILN 2061 ZW

1. In rising single doses

2. With and without a 64 g fat breakfast at one selected dose

Detailed Description

Not available

Study Timeline

• Study Start: 2001-06
• Primary Completion: 2001-09
• Status Verified: 2014-10
• Study First Submitted: 2014-10-17
• Study First Submitted QC: 2014-10-17
• Last Update Submitted: 2014-10-17
• Study First Posted: 2014-10-20
• Last Update Posted: 2014-10-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 103

Inclusion Criteria

• Healthy male subjects as determined by results of screening
• Signed written informed consent in accordance with good clinical practice (GCP) and local legislation
• Age ≥ 18 and ≤ 50 years
• Broca ≥ - 20 % and ≤ + 20 %

Read More

Exclusion Criteria

• Any finding of the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
• History or current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders, including a history of viral hepatitis, or serological evidence of active Hepatitis B or Hepatitis C infection
• History of orthostatic hypotension, fainting spells and blackouts
• Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
• Chronic or relevant acute infections
• History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
• Intake of drugs with a long half-life (> 24 hours) within 1 month prior to administration
• Use of any drugs which might influence the results of the trial within 10 days prior to administration or during the trial
• Participation in another trial with an investigational drug within 1 month prior to administration or during the trial
• Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from smoking on trial days
• Alcohol abuse (> 60 g/day)
• Drug abuse
• Blood donation within 1 month prior to administration or during the trial
• Excessive physical activities within 5 days prior to administration or during the trial
• Any laboratory value outside the clinically accepted reference range and of clinical relevance
• History of any familial bleeding disorder

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
BILN 2061 ZW fixed dose fed	Standardized breakfast	-
BILN 2061 ZW single rising doses	BILN 2061 ZW single rising doses	-
BILN 2061 ZW fixed dose fasted	BILN 2061 ZW fixed dose	-
Placebo	Placebo	-
BILN 2061 ZW fixed dose fed	BILN 2061 ZW fixed dose	-

Primary Outcome Measures

Name	Time	Method
Number of patients with clinically relevant changes in vital signs (systolic and diastolic blood pressure, pulse rate)	Pre-dose, up to 48 hours after drug administration
Changes from baseline in laboratory tests	Pre-dose and 48 hours after drug administration
Number of patients with clinically relevant changes in 12-lead ECG	Pre-dose, up to 48 hours after drug administration
Changes from baseline in physical examination	Pre-dose and 48 hours after drug administration
Number of patients with adverse events	Up to 48 hours after drug administration
Global assessment of tolerability by the investigator on a 4-point scale	Up to 48 hours after drug administration
Maximum concentration of the analyte in plasma after a single dose administration (Cmax)	up to 48 hours after drug administration
Area under the concentration-time curve of the analyte in plasma from time 0 to infinity (AUC0-infinity)	up to 48 hours after drug administration
Time to reach Cmax following a single dose administration (tmax)	up to 48 hours after drug administration
Elimination half-life of the analyte in plasma (t1/2)	up to 48 hours after drug administration
Total oral clearance of the analyte from plasma after oral administration, divided by F (bioavailability factor) (CL/F)	up to 48 hours after drug administration
Total mean residence time of the analyte in plasma (MRT)	up to 48 hours after drug administration
Apparent volume of distribution during the terminal elimination phase (Vz/F)	up to 48 hours after drug administration
Amount of intact drug excreted in urine (Au)	up to 48 hours after drug administration